Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says

This article was originally published in The Tan Sheet

Executive Summary

Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends
Advertisement

Related Content

Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
NCEP Statin Recommendations Challenged By CSPI, Researchers
NCEP Statin Recommendations Challenged By CSPI, Researchers
NCEP Statin Recommendations Challenged By CSPI, Researchers
CARDS Researchers Bet On Statins For CVD Prevention In Type 2 Diabetics
CARDS Researchers Bet On Statins For CVD Prevention In Type 2 Diabetics
Mevacor Behind-The-Counter Status Is “Not Necessary,” J&J/Merck Says
Mevacor Behind-The-Counter Status Is “Not Necessary,” J&J/Merck Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS097070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel